Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Merck
US Department of Justice
Covington
Cipla
Citi
Fish and Richardson

Generated: May 24, 2019

DrugPatentWatch Database Preview

Human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant - Biologic Drug Details

« Back to Dashboard

Summary for human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant
Tradenames:1
Patents:5
Applicants:1
BLAs:1
Suppliers: see list2

US Patents for human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Merck Sharp & Dohme Corp. GARDASIL human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant INJECTION, SUSPENSION 125126 001 2006-06-08 ➤ Sign Up Chevron Phillips Chemical Company LP (The Woodlands, TX) ➤ Sign Up search
Merck Sharp & Dohme Corp. GARDASIL human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant INJECTION, SUSPENSION 125126 001 2006-06-08 ➤ Sign Up SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) ➤ Sign Up search
Merck Sharp & Dohme Corp. GARDASIL human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant INJECTION, SUSPENSION 125126 001 2006-06-08 ➤ Sign Up SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) ➤ Sign Up search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2001 00033 Denmark ➤ Sign Up PRODUCT NAME: REKOMBINANT HUMANT OSTEOGENT PROTEIN-1: BMP-7; REG. NO/DATE: EU/1/01/179/001 20010517
C/GB10/045 United Kingdom ➤ Sign Up PRODUCT NAME: DENOSUMAB, IMMUNOGLOBULIN G2, ANTI-(HUMAN TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 11 (HUMAN OSTEOCLAST DIFFERENTIATION FACTOR)) (HUMAN MONOCLONAL AMG162 HEAVY CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL AMG162 LIGHT CHAIN, DIMER; REGISTERED: UK EU/1/10/618/001 20100526; UK EU/1/10/618/002 20100526; UK EU/1/10/618/003 20100526; UK EU/1/10/618/004 20100526
2016 00031 Denmark ➤ Sign Up PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; NAT. REG. NO/DATE: EU/1/98/067/003-004 20140326; FIRST REG. NO/DATE: EU EU/1/98/067 20140326
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Covington
Teva
Chubb
Cantor Fitzgerald
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.